Drug Profile
Research programme: tetrahydrofolate dehydrogenase inhibitors - Promiliad Biopharma/ Spero Therapeutics
Alternative Names: Dihydrofolate reductase inhibitors -Promiliad Biopharma/ Spero TherapeuticsLatest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator University of Connecticut
- Developer Promiliad Biopharma; Spero Therapeutics
- Class Anti-infectives; Small molecules
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections; Gram-positive infections; Urinary tract infections
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Gram-negative-infections in USA (IV)
- 28 Feb 2020 No recent reports of development identified for research development in Gram-negative-infections in USA (PO)
- 28 Feb 2020 No recent reports of development identified for research development in Gram-positive-infections in USA (IV)